Crosstalk between human IgG isotypes and murine effector cells

Journal of Immunology

Volumn 189, Issue 7, 2012, Pages 3430-3438

  Overdijk, Marije B ^a   Verploegen, Sandra ^a   Buijsse, Antonio Ortiz ^a   Vink, Tom ^a   Leusen, Jeanette H W ^b   Bleeker, Wim K ^a   Parren, Paul W H I ^a  

^a GENMAB   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CD20 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FC RECEPTOR; FC RECEPTOR IIB; FC RECEPTOR IV; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPENDENT CELLULAR PHAGOCYTOSIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; LEUKEMIA; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; BINDING SITES, ANTIBODY; BONE MARROW CELLS; CELL LINE, TUMOR; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; KILLER CELLS, NATURAL; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; NEUTROPHILS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84866534949     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200356     Document Type: Article

References (37)

1. Stern, M., and R. Herrmann. 2005. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit. Rev. Oncol. Hematol. 54: 11-29. (Pubitemid 40387003)
2. Bruhns, P., B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, and M. Daëron. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725.
3. van de Winkel, J. G., and C. L. Anderson. 1991. Biology of human immunoglobulin G Fc receptors. J. Leukoc. Biol. 49: 511-524.
4. Parren, P. W., P. A. Warmerdam, L. C. Boeije, J. Arts, N. A. Westerdaal, A. Vlug, P. J. Capel, L. A. Aarden, and J. G. van de Winkel. 1992. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J. Clin. Invest. 90: 1537-1546.
5. Parren, P. W., P. A. Warmerdam, L. C. Boeije, P. J. Capel, J. G. van de Winkel, and L. A. Aarden. 1992. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3. J. Immunol. 148: 695-701.
6. Brüggemann, M., G. T. Williams, C. I. Bindon, M. R. Clark, M. R. Walker, R. Jefferis, H. Waldmann, and M. S. Neuberger. 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166: 1351-1361. (Pubitemid 18051427)
7. Dijstelbloem, H. M., J. G. van de Winkel, and C. G. Kallenberg. 2001. Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol. 22: 510-516. (Pubitemid 32778579)
8. Nimmerjahn, F., P. Bruhns, K. Horiuchi, and J. V. Ravetch. 2005. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23: 41-51. (Pubitemid 41019656)
9. Steplewski, Z., L. K. Sun, C. W. Shearman, J. Ghrayeb, P. Daddona, and H. Koprowski. 1988. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc. Natl. Acad. Sci. USA 85: 4852-4856.
10. Isaacs, J. D., M. R. Clark, J. Greenwood, and H. Waldmann. 1992. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J. Immunol. 148: 3062-3071.
11. Loisel, S., M. Ohresser, M. Pallardy, D. Daydé, C. Berthou, G. Cartron, and H. Watier. 2007. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit. Rev. Oncol. Hematol. 62: 34-42. (Pubitemid 46330797)
12. Bleeker, W. K., J. J. Lammerts van Bueren, H. H. van Ojik, A. F. Gerritsen, M. Pluyter, M. Houtkamp, E. Halk, J. Goldstein, J. Schuurman, M. A. van Dijk, et al. 2004. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J. Immunol. 173: 4699-4707. (Pubitemid 39280705)
13. Teeling, J. L., R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. Parren, C. E. Hack, M. Dechant, et al. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800. (Pubitemid 39202289)
14. Tao, M. H., and S. L. Morrison. 1989. Studies of aglycosylated chimeric mousehuman IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143: 2595-2601.
15. Otten, M. A., G. J. van der Bij, S. J. Verbeek, F. Nimmerjahn, J. V. Ravetch, R. H. Beelen, J. G. van de Winkel, and M. van Egmond. 2008. Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J. Immunol. 181: 6829-6836.
16. Elsässer, D., T. Valerius, R. Repp, G. J. Weiner, Y. Deo, J. R. Kalden, J. G. van de Winkel, G. T. Stevenson, M. J. Glennie, and M. Gramatzki. 1996. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 87: 3803-3812. (Pubitemid 26129608)
17. Tiroch, K., B. Stockmeyer, C. Frank, and T. Valerius. 2002. Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicity. J. Immunol. 168: 3275-3282. (Pubitemid 34250388)
18. Schneider-Merck, T., J. J. Lammerts van Bueren, S. Berger, K. Rossen, P. H. van Berkel, S. Derer, T. Beyer, S. Lohse, W. K. Bleeker, M. Peipp, et al. 2010. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J. Immunol. 184: 512-520.
19. Overdijk, M. B., S. Verploegen, J. H. van den Brakel, J. J. Lammerts van Bueren, T. Vink, J. G. van de Winkel, P. W. Parren, and W. K. Bleeker. 2011. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J. Immunol. 187: 3383-3390.
20. Syed, S. N., S. Konrad, K. Wiege, B. Nieswandt, F. Nimmerjahn, R. E. Schmidt, and J. E. Gessner. 2009. Both FcgammaRIV and FcgammaRIII are essential receptors mediating type II and type III autoimmune responses via FcRgamma-LAT-dependent generation of C5a. Eur. J. Immunol. 39: 3343-3356.
21. Nimmerjahn, F., A. Lux, H. Albert, M. Woigk, C. Lehmann, D. Dudziak, P. Smith, and J. V. Ravetch. 2010. FcgRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc. Natl. Acad. Sci. USA 107: 19396-19401.
22. Carter, P. J. 2006. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6: 343-357.
23. Jefferis, R. 2007. Antibody therapeutics: isotype and glycoform selection. Expert Opin. Biol. Ther. 7: 1401-1413. (Pubitemid 47475656)
24. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8: 34-47.
25. Stapleton, N. M., J. T. Andersen, A. M. Stemerding, S. P. Bjarnarson, R. C. Verheul, J. Gerritsen, Y. Zhao, M. Kleijer, I. Sandlie, M. de Haas, et al. 2011. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat. Commun. 2: 599.
26. Ober, R. J., C. G. Radu, V. Ghetie, and E. S. Ward. 2001. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol. 13: 1551-1559. (Pubitemid 33133882)
27. Natsume, A., M. In, H. Takamura, T. Nakagawa, Y. Shimizu, K. Kitajima, M. Wakitani, S. Ohta, M. Satoh, K. Shitara, and R. Niwa. 2008. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 68: 3863-3872.
28. Niwa, R., A. Natsume, A. Uehara, M. Wakitani, S. Iida, K. Uchida, M. Satoh, and K. Shitara. 2005. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J. Immunol. Methods 306: 151-160. (Pubitemid 41739846)
29. van der Neut Kolfschoten, M., J. Schuurman, M. Losen, W. K. Bleeker, P. Martínez-Martínez, E. Vermeulen, T. H. den Bleker, L. Wiegman, T. Vink, L. A. Aarden, et al. 2007. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317: 1554-1557. (Pubitemid 47417435)
30. Lewis, K. B., B. Meengs, K. Bondensgaard, L. Chin, S. D. Hughes, B. Kjaer, S. Lund, and L. Wang. 2009. Comparison of the ability of wild type and stabilized human IgG(4) to undergo Fab arm exchange with endogenous IgG(4) in vitro and in vivo. Mol. Immunol. 46: 3488-3494.
31. Angal, S., D. J. King, M. W. Bodmer, A. Turner, A. D. Lawson, G. Roberts, B. Pedley, and J. R. Adair. 1993. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol. Immunol. 30: 105-108. (Pubitemid 223036868)
32. Bloom, J. W., M. S. Madanat, D. Marriott, T. Wong, and S. Y. Chan. 1997. Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci. 6: 407-415. (Pubitemid 27079933)
33. Schuurman, J., G. J. Perdok, A. D. Gorter, and R. C. Aalberse. 2001. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol. Immunol. 38: 1-8. (Pubitemid 32718637)
34. Boross, P., J. H. Jansen, S. de Haij, F. J. Beurskens, C. E. van der Poel, L. Bevaart, M. Nederend, J. Golay, J. G. van de Winkel, P. W. Parren, and J. H. Leusen. 2011. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 96: 1822-1830.
35. Bevaart, L., M. J. Jansen, M. J. van Vugt, J. S. Verbeek, J. G. van de Winkel, and J. H. Leusen. 2006. The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res. 66: 1261-1264. (Pubitemid 43259901)
36. Nimmerjahn, F., and J. V. Ravetch. 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310: 1510-1512. (Pubitemid 41746349)
37. Oflazoglu, E., I. J. Stone, L. Brown, K. A. Gordon, N. van Rooijen, M. Jonas, C. L. Law, I. S. Grewal, and H. P. Gerber. 2009. Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br. J. Cancer 100: 113-117.